Anna M De Kort, Kanishk Kaushik, H Bea Kuiperij, Lieke Jäkel, Hao Li, Anil M Tuladhar, Gisela M Terwindt, Marieke J H Wermer, Jurgen A H R Claassen, Catharina J M Klijn, Marcel M Verbeek, Roy P C Kessels, Floris H B M Schreuder
BACKGROUND: Patients with sporadic cerebral amyloid angiopathy (sCAA) frequently report cognitive or neuropsychiatric symptoms. The aim of this study is to investigate whether in patients with sCAA, cognitive impairment and neuropsychiatric symptoms are associated with a cerebrospinal fluid (CSF) biomarker profile associated with Alzheimer's disease (AD). METHODS: In this cross-sectional study, we included participants with sCAA and dementia- and stroke-free, age- and sex-matched controls, who underwent a lumbar puncture, brain MRI, cognitive assessments, and self-administered and informant-based-questionnaires on neuropsychiatric symptoms...
May 4, 2024: Alzheimer's Research & Therapy